Ожирение как прогностический аспект фибрилляции предсердий у лиц пожилого возраста (обзор литературы)

Автор: Крючков Илья Андреевич, Львов Николай Игоревич, Дадалов Саид-Магомед Адамович, Эльмурзаева Анжела Абуевна, Клецова Марина Владимировна

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Клиническая медицина

Статья в выпуске: 3 (39), 2019 года.

Бесплатный доступ

Ожирение является серьезной проблемой общественного здравоохранения во всем мире, и выступает независимым фактором риска в частоте и прогрессировании фибрилляции предсердий. Рост показателей заболеваемости и смертности, связанные с данным заболеванием, требует тщательного рассмотрения эпидемиологической и патофизиологической взаимосвязи с ожирением.

Фибрилляция предсердий, ожирение

Короткий адрес: https://sciup.org/143172216

IDR: 143172216

Список литературы Ожирение как прогностический аспект фибрилляции предсердий у лиц пожилого возраста (обзор литературы)

Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34: 2746-51.
Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study. Circulation. 2011;123:1501-8.
Tedrow UB, Conen D, Ridker PM et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol. 2010;55:2319-27.
Elagizi A, Kachur S, Lavie CJ et al. An overview and update of obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018;61:142-50.
Wong CX ST, Sun MT, Mahajan R et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139-52.
Foy AH, Mandrola J, Liu G et al. Relation of obesity to new-onset atrial fibrillation and atrial flutter in adults. Am J Cardiol. 2018;121:1072-75.
Sandhu RK, Conen D, Tedrow UB et al. Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014;3:e000916.
Karasoy D, Bo Jensen T, Hansen ML et al. Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace. 2013;15:781-6.
Berkovitch A, Kivity S, Klempfner R et al. Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults. Am Heart J. 2016;173:41-8.
Lee H, Choi EK, Lee SH et al. Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study. Int J Cardiol. 2017;240:221-7.
Pandey A, Gersh BJ, McGuire DK et al. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC Clin Electrophysiol. 2016;2:355-63.
Sandhu RK, Ezekowitz J, Andersson U et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37:2869-78.
Wang J, Yang YM, Zhu J et al. Overweight is associated with improved survival and outcomes in patients with atrial fibrillation. Clin Res Cardiol. 2014;103:533-42.
Zhu W, Wan R, Liu F et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. J Am Heart Assoc. 2016;5:e004006.
Qureshi WT, Alirhayim Z, Blaha MJ et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry ford exercise testing (FIT) project. Circulation. 2015;131:1827-34.
Pathak RK, Elliott A, Middeldorp ME et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol. 2015;66:985-96.
Malmo V, Nes BM, Amundsen BH et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. 2016;133:466-73.
Nazare JA, Smith J, Borel AL et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am J Cardiol. 2015;115:307-15.
De Schutter A, Lavie CJ, Kachur S et al. Body composition and mortality in a large cohort with preserved ejection fraction: untangling the obesity paradox. Mayo Clin Proc. 2014;89:1072-9.
Bowman K, Atkins JL, Delgado J et al. Central adiposity and the overweight risk paradox in aging: follow-up of 130,473 UK Biobank participants. Am J Clin. Nutr. 2017;106:130-5.
Fenger-Gron M, Overvad K, Tjoneeland A et al. Lean body mass is the predominant anthropometric risk factor for atrial fibrillation. J Am Coll Cardiol. 2017;69:2488-97.
Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122:352-68.
Nguyen Dinh Cat A, Briones AM, Callera GE et al. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension. 2011;58:479-88.
Briones AM, Nguyen Din Cat A, Callera GE. Adipocytes produce aldosterone through calcineurin-dependent signalling pathways. Implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-78.
Olivier A, Pitt B, Girerd N et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity, Insight from the EMPHASIS-HF trial. Eur J Heart Fail. 2017;19:1186-97.
Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31-9.
De Sensi F, De Potter TM, Cresti A et al. Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther. 2015;5:364-73.
Alpert MA, Lavie CJ, Agrawal et al. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations and management. Transl Res. 2014;164:345-56.
Lavie CJ, Pandey A, Lau DH et al. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis. J Am Coll Cardiol. 2017;70:2022-35.
Kumar PV, Mundi A, Caldito G et al. Higher body mass index is an independent predictor of left atrial enlargement. Int J Clin Med. 2011;2:556-60.
Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017;38:1294-1302.
Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153:907-17.
Muhib S, Fujino T, Sato N et al. Epicardial adipose tissue is associated with prevalent atrial fibrillation in patients with hypertrophic cardiomyopathy. Int Heart J. 2013;54:297-303.
Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest. 2015;125:478-86.
Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11:363-71.
Al Chekakie MO, Welles CC, Metoyer R et al. Epicardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010;56:784-8.
Tsao H-M, Hu W-C, Wu M-H et al. Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium in patients with atrial fibrillation and effect of recurrence after ablation. Am J Cardiol. 2011;107:1498-1503.
Nakamori S, Nezafat M, Nho LH et al. Left atrial epicardial fat volume is associated with atrial fibrillation: a prospective cardiovascular magnetic resonance 3D Dixon study. J Am Heart Assoc. 2018;7:e008232.
Smorodinova N, Blaha M, Melenovsky V et al. Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm. PLoS One. 2017;12:e01726911.
Venteclef N, Guglielmi V, Balse E Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J. 2013. pp. 1-12.
Hatem SN, Redheuil A, Gandjbakhch E. Cardiac adipose tissue and atrial fibrillation: the perils of adiposity. Cardiovasc Res. 2016;109:502-9.
Verheule S, Tuyls E, Gharaviri A et al. Loss of continuity in the thin epicardial layer because of endomysial fibrosis increases the complexity of atrial fibrillatory conduction. Circ Arrhythm Electrophysiol. 2013;6:202-11.
Lin Y-K, Chen Y-C, Chen J-H et al. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol. 2012;107:293.
Iwasaki YK, Shi Y, Benito B et al. Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm. 2012;9:1409-16.
Balcioglu AS, Ciçek D, Akinci S et al. Arrhythmogenic evidence for epicardial adipose tissue: heart rate variability and turbulence are influenced by epicardial fat thickness. Pacing Clin Electrophysiol. 2015;38:99e106.
Pokushalov E, Kozlov B, Romanov A et al. Botulinum toxin injection in epicardial fat pads can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot study. J Am Coll Cardiol. 2014;64:628-9.
Pokushalov E, Kozlov B, Romanov A et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: one year follow up of a randomized pilot study. Circ Arrhythm Electrophysiol. 2015;8:1334-41.
Oh S, Choi E-K, Zhang Y et al. Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation. Circ Arrhyth Electrophysiol. 2011;4:560-5.
Chao TF, Hung HM, Tsao YJ et al. Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation. PLoS One. 2013;8:e74926.
Antonopoulos AS, Sanna F, Sabharwal N et al. Detecting human coronary inflammation by imaging perivascular fat. piiSci Trans Med 2017. 2017;9:eaal2658.

Еще

Статья обзорная